|Bid||74.24 x 0|
|Ask||74.38 x 0|
|Day's Range||73.50 - 74.44|
|52 Week Range||73.01 - 86.92|
|Beta (5Y Monthly)||0.53|
|PE Ratio (TTM)||18.58|
|Earnings Date||Feb 02, 2022|
|Forward Dividend & Yield||3.00 (4.08%)|
|Ex-Dividend Date||Mar 04, 2021|
|1y Target Est||92.39|
Subscribe to Yahoo Finance Plus to view Fair Value for NOVN.SWLearn more
Deciphera (DCPH) announces a corporate restructuring plan to prioritize development of vimseltinib and DCC-3116, streamline commercial operations and reduce workforce by almost 35%. Shares rise.
More than a century after Marie and Pierre Curie first discovered radium, a biotech startup by their name is building on the promise of radiotherapy with hopes of making it a less dangerous undertaking.
Novartis is keeping all options open for the future of its generics division Sandoz, its chairman said in an interview with Swiss TV channel TeleZüri to be broadcast on Tuesday. Asked whether Novartis could merge Sandoz with either Israel's Teva or U.S.-based Viatris or divest it, Joerg Reinhardt said: "All options are open for us." Reinhardt said Novartis's innovative pharma business and the generics business had drifted further apart over the last years so it made sense to examine options now.